Defence Therapeutics Inc.
DTCFF
$0.35
-$0.02-5.41%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -12.66% | 1.65% | -72.60% | -75.91% | -61.17% |
| Depreciation & Amortization | -46.67% | -42.62% | -27.88% | -22.31% | 130.41% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.21% | -14.86% | -72.51% | -76.66% | -64.27% |
| Operating Income | 1.21% | 14.86% | 72.51% | 76.66% | 64.27% |
| Income Before Tax | -58.49% | -10.93% | 67.17% | 71.87% | 71.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -58.49% | -10.93% | 67.17% | 71.87% | 71.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -58.49% | -10.93% | 67.17% | 71.87% | 71.24% |
| EBIT | 1.21% | 14.86% | 72.51% | 76.66% | 64.27% |
| EBITDA | 0.17% | 14.30% | 72.78% | 76.99% | 64.82% |
| EPS Basic | -30.31% | 5.91% | 71.50% | 74.84% | 72.93% |
| Normalized Basic EPS | -33.06% | 10.68% | 73.11% | 76.26% | 74.08% |
| EPS Diluted | -30.31% | 5.91% | 71.50% | 74.84% | 72.93% |
| Normalized Diluted EPS | -33.06% | 10.68% | 73.11% | 76.26% | 74.08% |
| Average Basic Shares Outstanding | 20.04% | 17.68% | 13.96% | 9.86% | 6.05% |
| Average Diluted Shares Outstanding | 20.04% | 17.68% | 13.96% | 9.86% | 6.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |